Copyright © 2013 Knight Sac Media. All rights reserved.http://www.siliconinvestor.com/subject.aspx?subjectid=58109 Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit advancedcell.com. http://www.siliconinvestor.com/images/Logo380x132.pnghttp://www.siliconinvestor.com/subject.aspx?subjectid=5810938013210SavantACTC A patient improved from 20/400 to 20/40 after RPE implants. Hopefully, for those afflicted, the vision of the future... advancedcell.com  ACT Confirms Clinical Trial Participant Showed Improvement in Vision from 20/400 to 20/40 Following Treatment MARLBOROUGH, Mass.--(BUSINESS WIRE)--May 16, 2013-- Advance...http://www.siliconinvestor.com/readmsg.aspx?msgid=288991985/16/2013 7:30:03 PMSavantAdvanced Cell Technology, Inc. ("ACT" or the "Company"; OTCBB: ACTC) a leader in the field of regenerative medicine, announced today its first quarter financial results for the period ended March 31, 2013. The Company reported a loss from operations of $(5.8) million compared to a loss from operations of $(5.4) million...http://www.siliconinvestor.com/readmsg.aspx?msgid=288929705/14/2013 10:07:20 AMSavantACT Treats First Patient with Better Vision in Clinical Trial for Stargardt's Macular Dystrophy Patient Injected with 100,000 human embryonic stem cell-(hESC) derived Retinal Pigment Epithelial Cells MARLBOROUGH, Mass. — April 15, 2013 – Advanced Cell Technology, Inc.(“ACT”; OTCBB: ACTC), a leader in the field of re...http://www.siliconinvestor.com/readmsg.aspx?msgid=288358224/15/2013 11:18:52 AMSavantAdvanced Cell Technology, Cytomedix and Mesoblast to Provide Corporate and Clinical Updates at Regen Med Investor Day Apr 9, 2013 12:09:00 (ET) WASHINGTON, April 9, 2013 /PRNewswire via COMTEX/ -- At the first annual Regen Med Investor Day, Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), Cytomedix, Inc. (otc...http://www.siliconinvestor.com/readmsg.aspx?msgid=288303834/12/2013 1:58:54 AMSavantACT's Dr. Robert Lanza Voted Top 4 ""Most Influential People on Stem Cells"" Mar 12, 2013 08:30:03 (ET) MARLBOROUGH, Mass., Mar 12, 2013 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that chief scientific officer Robert Lanza...http://www.siliconinvestor.com/readmsg.aspx?msgid=287812613/15/2013 9:50:32 PMSavantAdvanced Cell Technology Receives Approval from Data Safety Monitoring Board (DSMB) to Initiate Treatment of Third Patient Cohort in All Three Clinical Trials Mar 14, 2013 08:30:01 (ET) MARLBOROUGH, Mass., Mar 14, 2013 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of...http://www.siliconinvestor.com/readmsg.aspx?msgid=287795643/15/2013 3:35:03 AMSavantAdvanced Cell Technology to Present at BIO-Europe Spring 2013 Mar 8, 2013 12:00:17 (ET) MARLBOROUGH, Mass., Mar 08, 2013 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that chairman and CEO Gary Rabin will present and particip...http://www.siliconinvestor.com/readmsg.aspx?msgid=287731853/11/2013 7:58:58 PMSavantAdvanced Cell Technology Announces Fourth-Quarter and Year-end Results Mar 7, 2013 16:00:00 (ET) MARLBOROUGH, Mass., Mar 07, 2013 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT", OTCBB: ACTC or the "Company"), a leader in the field of regenerative medicine, today announced fourth quarter and year-end fina...http://www.siliconinvestor.com/readmsg.aspx?msgid=287731773/11/2013 7:55:01 PMSavantAdvanced Cell Technology to Announce Fourth Quarter and Year-end Results on Thursday March 7th Mar 4, 2013 09:34:00 (ET) MARLBOROUGH, Mass., Mar 04, 2013 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT";OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that it will report fourth...http://www.siliconinvestor.com/readmsg.aspx?msgid=287632133/6/2013 12:16:40 PMFUBHOACT’s Clinical Partner Receives FDA Approval to Initiate Clinical Trial Using the Company’s hESC-derived Cells to Treat Severe Myopia UCLA’s Investigator IND Application for Embryonic Stem Cell-Based Clinical Trial to Evaluate Safety and Tolerability in Patients with Severe Myopia, or Nearsightedness, Approved by FDA...http://www.siliconinvestor.com/readmsg.aspx?msgid=287184102/11/2013 8:58:09 AMSavantRT...Aspirin implicated in AMD & SMD risk.. huffingtonpost.com  A pain-reliever known for its life-saving potential in the event of a heart attack might also be linked with age-related vision loss when taken regularly, according to a new study in the journal JAMA Internal Medicine. The findings show an association...http://www.siliconinvestor.com/readmsg.aspx?msgid=286817231/23/2013 11:19:00 AMSavantPatients with Better Vision to be Enrolled in ACT's Clinical Trials for Macular Degeneration Patients with 20/100 Vision Will Now be Eligible for Enrollment, Expanding Patient Base and Potentially Accelerating Pace of Trials MARLBOROUGH, Mass., Jan 22, 2013 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT...http://www.siliconinvestor.com/readmsg.aspx?msgid=286794841/22/2013 11:38:49 AMSavantAdvanced Cell Technology Announces Settlement of Litigation Agreement Resolves All Litigation Associated with Previously Issued Convertible Debentures MARLBOROUGH, Mass., Jan 17, 2013 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC or the "Company"), a leader in the field of regenerative me...http://www.siliconinvestor.com/readmsg.aspx?msgid=286716161/18/2013 12:37:43 AMSavant Advanced Cell Technology Achieves Clinical Milestone Company is Halfway through Groundbreaking Clinical Trials; Evidence of Engraftment and Function Observed; No Safety Issues Reported MARLBOROUGH, Mass., Jan 08, 2013 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC or the "Company"), a lead...http://www.siliconinvestor.com/readmsg.aspx?msgid=286505101/8/2013 12:07:24 PMSavantAdvanced Cell Technology to Present at Biotech Showcase(TM) 2013 MARLBOROUGH, Mass., Jan 07, 2013 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT") (ACTC), a leader in the field of regenerative medicine, announced today that chairman and CEO Gary Rabin will present at Biotech Showcase 2013 on Tuesday, Jan....http://www.siliconinvestor.com/readmsg.aspx?msgid=286504321/8/2013 11:36:21 AMSavantNew Scientist Magazine Selects ACT's Induced Pluripotent Stem (iPS) Cell-Derived Human Platelet Program As One of '10 Ideas That Will Shape The Year' 'Revolutionary Human Stem Cell Trial' Featured as Part of '2013 Smart Guide' MARLBOROUGH, Mass., Dec 20, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("AC...http://www.siliconinvestor.com/readmsg.aspx?msgid=2861799912/20/2012 6:28:58 PMSavantAdvanced Cell Technology Elects Not to Complete Reverse Split MARLBOROUGH, Mass., Dec 19, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC or the "Company"), a leader in the field of regenerative medicine, announced today that it will allow the shareholder approval it had received to comp...http://www.siliconinvestor.com/readmsg.aspx?msgid=2861541912/19/2012 3:36:19 PMSavantACT Announces Completion of Higher-Dosage Cohort in European Clinical Trial for Stargardt's Macular Dystrophy Halfway Point Now Reached In All Three Phase I/II Embryonic Stem Cell-Based Clinical Trials MARLBOROUGH, Mass., Dec 17, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC or the "...http://www.siliconinvestor.com/readmsg.aspx?msgid=2861541712/19/2012 3:35:31 PMFUBHOFirst human trials involving reprogrammed stem cells could come next year By Chris Welch on December 13, 2012 04:31 pm Email@chriswelch5COMMENTS [graphic] John B. Gurdon and Shinya Yamanaka earned a Nobel Prize for breakthroughs that came from their decades of stem cell research. Now it appears their work may ...http://www.siliconinvestor.com/readmsg.aspx?msgid=2860251512/13/2012 5:56:38 PMSavantRT... Regeneron Pharms EYLEA injection approved for the treatment of Wet Age-Related Macular Degeneration in Europe Co announces that EYLEA injection has been approved by the European Commission for the treatment of patients with neovascular age-related macular degeneration. EYLEA was approved for the treatment of neo...http://www.siliconinvestor.com/readmsg.aspx?msgid=2857083611/27/2012 4:21:43 PMSavantAdvanced Cell Technology Announces Interim Data from Its Three Ongoing Macular Degeneration Trials Company To Discuss Data as Part of Third Quarter Financial Results on Today's Conference Call MARLBOROUGH, Mass., Nov 08, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the...http://www.siliconinvestor.com/readmsg.aspx?msgid=2853612511/9/2012 11:25:44 AMSavantAdvanced Cell Technology Announces 2012 Third Quarter Results MARLBOROUGH, Mass., Nov 08, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC) ("ACT" or the "Company"), a leader in the field of regenerative medicine, announced today third quarter financial results for the period ended September 30, 2012. ...http://www.siliconinvestor.com/readmsg.aspx?msgid=2853611611/9/2012 11:23:42 AMSavantACT Announces Scotland's NHS Lothian as Additional Site for EU Clinical Trial Using hESC-Derived RPE Cells for Macular Degeneration Edinburgh-Headquartered UK National Health Service Provider is Third Designated Site for European Clinical Trial MARLBOROUGH, Mass., Aug 20, 2012 (BUSINESS WIRE) -- Advanced Cell Tec...http://www.siliconinvestor.com/readmsg.aspx?msgid=283641778/27/2012 11:29:41 AMSavantACT Comments on U.S. Appeals' Court's Dismissal Ruling in Case Challenging Federal Funding of Embryonic Stem Cell Research Ruling Should Clear Way for More Expedited NIH Approval of Funding of Company's hESC Lines and Other Funding Initiatives MARLBOROUGH, Mass., Aug 27, 2012 (BUSINESS WIRE) -- Advanced Cell Tech...http://www.siliconinvestor.com/readmsg.aspx?msgid=283639958/27/2012 10:20:03 AMSavantACTC Patient blog. 100K cells recipient... aisquared.com  She mentions she owns ACTC stock. (I'm hoping this is a real patient...checking) Best, S. http://www.siliconinvestor.com/readmsg.aspx?msgid=283235448/9/2012 4:55:29 AMSavantACT Announces First Dry AMD Patient Treated with Higher Dosage of Embryonic Stem Cell-Derived RPE Cells Patient with Dry Age-Related Macular Degeneration Injected with 100,000 Retinal Pigment Epithelial Cells at Wills Eye Institute in Philadelphia MARLBOROUGH, Mass., Aug 02, 2012 (BUSINESS WIRE) -- Advanced Cell ...http://www.siliconinvestor.com/readmsg.aspx?msgid=283235008/9/2012 2:35:27 AMSavantAdvanced Cell Technology Announces 2012 Second Quarter Results MARLBOROUGH, Mass., Aug 08, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT", OTCBB: ACTC)(the "Company"), a leader in the field of regenerative medicine, announced today second quarter financial results for the period ended June 30, 2012....http://www.siliconinvestor.com/readmsg.aspx?msgid=283234978/9/2012 2:28:52 AMSavantACT Treats 10th Patient in Embryonic Stem Cell Trials for Macular Degeneration Third Stargardt's Patient in EU Trial Treated with RPE Cells Derived from Human Embryonic Stem Cells at Moorfields Eye Hospital in London MARLBOROUGH, Mass., Jul 30, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB:...http://www.siliconinvestor.com/readmsg.aspx?msgid=283045067/31/2012 12:11:08 PMSavantADVANCED CELL TECHNOLOGY TO ANNOUNCE SECOND QUARTER FINANCIAL RESULTS ON WEDNESDAY, AUGUST 8TH Company to Hold Conference Call at 4:30 p.m. Eastern Time Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that it will release its second quarter fin...http://www.siliconinvestor.com/readmsg.aspx?msgid=283044987/31/2012 12:07:27 PMSavantACT Issued Broad Patent for Human RPE Cells Derived From All Types of Pluripotent Stem Cells New Australian Patent Covers Human RPE Cells Made From Range of Pluripotent Stem Cells, Including Both Embryonic Stem Cells and induced Pluripotent Stem (iPS) Cells MARLBOROUGH, Mass., Jul 26, 2012 (BUSINESS WIRE) -- Adv...http://www.siliconinvestor.com/readmsg.aspx?msgid=283044897/31/2012 12:06:20 PMSavantACT Announces First Stargardt Patient Treated With Higher Dosage of Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells Patient Injected with 100,000 RPE Cells at Wills Eye Institute MARLBOROUGH, Mass., Jul 12, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the f...http://www.siliconinvestor.com/readmsg.aspx?msgid=283044817/31/2012 12:05:16 PMSavantShares of Advanced Cell Technology Inc. (OTC: ACTC), a biotechnology company focused on the development and commercialization of human embryonic, induced pluripotency, and adult stem cell technology in field of regenerative medicine, has risen sharply in trading today. Advanced Cell Technology shares are currently t...http://www.siliconinvestor.com/readmsg.aspx?msgid=282566727/10/2012 9:54:42 AMSavantMay 18th.. Advanced Cell Technology to Present at World Stem Cells & Regenerative Medicine Congress in London Chairman and CEO Gary Rabin to Discuss Three Ongoing Clinical Trials Using Human Embryonic Stem Cell (hESC)-Derived Retinal Pigment Epithelial (RPE) Cells to Treat Macular Degeneration MARLBOROUGH, Mass....http://www.siliconinvestor.com/readmsg.aspx?msgid=282080826/15/2012 1:11:19 AMSavantAdvanced Cell Technology to Present at the 2012 Bio International Convention and the Clinical Outlooks for Regenerative Medicine Meeting MARLBOROUGH, Mass., Jun 14, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the ...http://www.siliconinvestor.com/readmsg.aspx?msgid=282080806/15/2012 1:07:58 AMSavantAdvanced Cell Technology Announces 2012 First Quarter Results MARLBOROUGH, Mass., May 08, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today first quarter financial results for the period ended March 31, 2012. The Company rep...http://www.siliconinvestor.com/readmsg.aspx?msgid=281528955/17/2012 7:09:24 PMSavantRT>>Osiris stem-cell therapy wins Canadian approval BOSTON (MarketWatch) -- Shares of Osiris Therapeutics jumped 14% to $5.60 in after-hours trading Thursday on news that Canadian regulators have approved its product Prochymal for the treatment of acute graft-vs-host disease, or GVHD, in children. GVHD is a life-t...http://www.siliconinvestor.com/readmsg.aspx?msgid=281528925/17/2012 7:07:34 PMSavant Advanced Cell Technology Announces Webcast of Corporate Presentation at Annual Shareholders' Meeting Today Webcast to Commence at 9:15 a.m. PDT After Formal Portion of Meeting has Concluded MARLBOROUGH, Mass., Apr 26, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the f...http://www.siliconinvestor.com/readmsg.aspx?msgid=281194045/2/2012 8:46:18 AMSavantACT Announces Approval of Bascom Palmer Eye Institute as Additional Site for Stem Cell Clinical Trial for dry Age-Related Macular Degeneration Ranked as Number One Eye Hospital Eight Years in a Row by U.S. News & World Report, Bascom Palmer Will Participate as Site for ACT’s Phase I/II Clinical Trial Using Human Emb...http://www.siliconinvestor.com/readmsg.aspx?msgid=280669944/7/2012 11:22:26 AMSavanthttp://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8125202 Filed on: March 8, 2012http://www.siliconinvestor.com/readmsg.aspx?msgid=280183543/17/2012 2:23:16 AMSavantTiming and Pace of Trials.... Feb 16 Timing and Pace of Our Clinical Trials Greetings, As you are undoubtedly aware, last July we initiated the first-ever clinical trials using a cell therapy derived from human embryonic stem cells (hESCs) to treat various forms of macular degeneration. The end goal for ou...http://www.siliconinvestor.com/readmsg.aspx?msgid=280182093/16/2012 10:49:26 PMSavantView: Annual Data | Quarterly DataAll numbers in thousandsPeriod Ending Dec 31, 2011 Sep 30, 2011 Jun 30, 2011 Mar 31, 2011Total Revenue 66 133 154 154 Cost of Revenue23 17 282 23 Gross Profit 43 116 (128) 131 Operating ExpensesResearch Development2,979 4,036 1,532 1,475 Selling General and Administrative2,831 2,9...http://www.siliconinvestor.com/readmsg.aspx?msgid=280156983/15/2012 8:37:36 PMSavant8-Mar-2012Unregistered Sale of Equity Securities, Other Events, Financial St Item 3.02. Unregistered Sales of Equity Securities. The information set forth under Item 8.01 in this current report on Form 8-K is incorporated by reference into this Item 3.02. The shares that we agreed to issue to Cranshire will be issued...http://www.siliconinvestor.com/readmsg.aspx?msgid=280156923/15/2012 8:34:29 PMSavantMARLBOROUGH, Mass.--(BUSINESS WIRE)-- Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the company’s chairman and CEO, Gary Rabin, will be presenting at Roth Capital Partners’ 24th Annual ROTH Conference, March 11-14. Mr. Rabin’s presentatio...http://www.siliconinvestor.com/readmsg.aspx?msgid=280156813/15/2012 8:27:54 PMSavantOn March 14, 2012, Advanced Cell Technology, Inc. (the "Company") issued a press release regarding a proposed reverse stock split and other matters to be acted upon at the Company's annual meeting of shareholders to be held on April 26, 2012. A copy of the Company's press release is attached hereto as Exhibit 99.1. ...http://www.siliconinvestor.com/readmsg.aspx?msgid=280156713/15/2012 8:24:38 PMSavantAdvanced Cell Technology Announces 2011 Financial Results MARLBOROUGH, Mass., Mar 01, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT", OTCBB: ACTC), a leader in the field of regenerative medicine, today announced year-end results for the year ended December 31, 2011. The Company utilized $13.6 millio...http://www.siliconinvestor.com/readmsg.aspx?msgid=279837273/1/2012 5:40:54 PMFUBHONEWARK, Calif., Feb. 2, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq: STEM - News) today announced that the U.S. Food and Drug Administration (FDA) has authorized the initiation of a Phase I/II clinical trial of the Company's proprietary HuCNS-SC(R) product candidate (purified human neural stem cells) in dry age-r...http://www.siliconinvestor.com/readmsg.aspx?msgid=279227252/2/2012 10:03:10 AMSavantAudio interview on NPR w/ACTC sciencefriday.com  Stem cell therapy, audio button upper lefthttp://www.siliconinvestor.com/readmsg.aspx?msgid=279124761/28/2012 2:46:38 PMSavantACT Announces that Additional Patient with Stargardt's Disease Has Undergone Embryonic Stem Cell Transplantation at UCLA's Jules Stein Eye Institute MARLBOROUGH, Mass., Jan 25, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced tod...http://www.siliconinvestor.com/readmsg.aspx?msgid=279042501/25/2012 9:20:21 AMSavant WSJ BLOG/Health: Some Promising Findings on Embryonic Stem Cells Last Update: 1/23/2012 5:02:33 PM (This story has been posted on The Wall Street Journal Online's Health Blog at blogs.wsj.com  By Katherine Hobson Very early results fromresearch into embryonic stem cell treatments suggest that the therapy was ...http://www.siliconinvestor.com/readmsg.aspx?msgid=279010231/24/2012 12:38:13 AMFUBHOThe results reported Monday could help lift some of that pall. They come from the second clinical trial involving the stem cells, using a therapy developed by the company Advanced Cell Technology to treat macular degeneration, a leading cause of blindness. “It’s a big step forward for regenerative medicine,” said D...http://www.siliconinvestor.com/readmsg.aspx?msgid=279002811/23/2012 6:51:25 PM